更多
APP下载
合作
商城
签到
Chinese scientists identify oral drug VV116 as promising Nipah virus treatment
2026-1-27 14:18
菲律宾商报
0

(ECNS) --

The research was led by professors Xiao Gengfu, Zhang Leike and Shan Chao from the Wuhan Institute of Virology, and Hu Tianwen from Vigonvita Life Sciences Co., Ltd.

Researchers reported that V116, a prodrug targeting the viral RNA-dependent RNA polymerase (RdRp), and its active metabolites significantly inhibited NiV replication in laboratory experiments. The drug was effective against both the Malaysian (NiV-M) and Bangladeshi (NiV-B) strains of the virus.

This breakthrough marks the first confirmation of VV116's therapeutic potential against NiV.

The study titled "The oral nucleoside drug VV116 is a promising candidate for treating Nipah virus infection," was published in the international journal Emerging Microbes & Infections.

In January 2026, new cases and deaths were reported in West Bengal, India, prompting authorities to isolate nearly 100 close contacts.

VV116 (deuterium remdesivir hydrobromide tablet) is a novel oral nucleoside antiviral drug that has previously been approved in Uzbekistan and China for the treatment of COVID-19.

Nipah virus was first identified during an outbreak in Malaysia in 1998, and is now recognized as a high-risk pathogen with a fatality rate of 40%–70%.

From 2023 to now, repeated outbreaks in India and Bangladesh have shown a growing trend in both scale and geographic spread.

Due to its broad host range, high mortality rate, and the absence of approved drugs or vaccines, the World Health Organization (WHO) has classified NiV as a priority pathogen posing a serious regional threat.

社区好帖更多帖子
返回顶部